The Wall Street firm said this stock is a category leader for model-informed drug development (MIDD), or simulations for biotech drug trials.
You are here: Home / This unique biotech play should rally more than 35% ahead, BTIG says
Market News and Views
The Wall Street firm said this stock is a category leader for model-informed drug development (MIDD), or simulations for biotech drug trials.